MX2021012154A - Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico. - Google Patents

Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico.

Info

Publication number
MX2021012154A
MX2021012154A MX2021012154A MX2021012154A MX2021012154A MX 2021012154 A MX2021012154 A MX 2021012154A MX 2021012154 A MX2021012154 A MX 2021012154A MX 2021012154 A MX2021012154 A MX 2021012154A MX 2021012154 A MX2021012154 A MX 2021012154A
Authority
MX
Mexico
Prior art keywords
chronic pain
drug delivery
transmucosal drug
delivery devices
pain relief
Prior art date
Application number
MX2021012154A
Other languages
English (en)
Inventor
Andrew Finn
Niraj Vasisht
Original Assignee
Biodelivery Sciences Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodelivery Sciences Int Inc filed Critical Biodelivery Sciences Int Inc
Publication of MX2021012154A publication Critical patent/MX2021012154A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente se proporcionan métodos para tratar el dolor crónico mediante la administración de dosis bajas de buprenorfina dos veces al día (o una vez al día) a través de un dispositivo de suministro transmucosal de fármacos. Los métodos y dispositivos tratan de manera eficiente el dolor crónico sin efectos secundarios significativos.
MX2021012154A 2011-12-21 2014-06-18 Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico. MX2021012154A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161578755P 2011-12-21 2011-12-21

Publications (1)

Publication Number Publication Date
MX2021012154A true MX2021012154A (es) 2021-11-03

Family

ID=48669710

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014007350A MX362217B (es) 2011-12-21 2012-12-21 Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico.
MX2021012154A MX2021012154A (es) 2011-12-21 2014-06-18 Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014007350A MX362217B (es) 2011-12-21 2012-12-21 Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico.

Country Status (16)

Country Link
EP (1) EP2793870A4 (es)
JP (1) JP6255349B2 (es)
KR (4) KR102026321B1 (es)
CN (2) CN104125828A (es)
AU (4) AU2012358308A1 (es)
BR (1) BR112014015329A8 (es)
CA (1) CA2859859A1 (es)
EA (2) EA034529B1 (es)
HK (1) HK1203365A1 (es)
IL (2) IL233075A0 (es)
IN (1) IN2014DN06117A (es)
MX (2) MX362217B (es)
SG (3) SG10202012743WA (es)
UA (1) UA118540C2 (es)
WO (1) WO2013096811A2 (es)
ZA (1) ZA201804381B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021163529A2 (en) * 2020-02-13 2021-08-19 Biodelivery Sciences International, Inc. Methods of treatment with buprenorphine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19960154A1 (de) * 1999-12-14 2001-07-12 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
JP2003522144A (ja) * 2000-02-08 2003-07-22 ユーロ−セルティーク，エス．エイ． オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
CA2445346C (en) 2001-04-27 2010-04-06 Ajinomoto Co., Inc. N-substituted pyrazole-o-glycoside derivatives and therapeutic agent for diabetes containing the same
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
DE102005007859A1 (de) * 2005-02-21 2006-08-24 Lts Lohmann Therapie-Systeme Ag Vefahren für eine medikamentöse Kombinations-Behandlung, sowie hierfür geeignete Arzneimittel-Kombinationen
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US9522188B2 (en) 2005-12-13 2016-12-20 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
KR20090007418A (ko) 2006-04-12 2009-01-16 스피날모우션, 인코포레이티드 후방 척추 장치 및 방법
DK2054031T3 (en) 2006-07-21 2016-05-17 Biodelivery Sciences Int Inc Transmucosal delivery devices with improved uptake
EP1897543A1 (en) * 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
US20090270438A1 (en) * 2006-10-18 2009-10-29 Clive Booles Novel compositions and formulations
GB0620661D0 (en) * 2006-10-18 2006-11-29 Pharmasol Ltd Novel compounds
GB2447016A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Buprenorphine/naloxone compositions
WO2010008863A1 (en) * 2008-06-23 2010-01-21 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions

Also Published As

Publication number Publication date
CA2859859A1 (en) 2013-06-27
CN104125828A (zh) 2014-10-29
WO2013096811A2 (en) 2013-06-27
CN110123792A (zh) 2019-08-16
AU2012358308A1 (en) 2014-07-24
UA118540C2 (uk) 2019-02-11
EP2793870A4 (en) 2016-02-17
MX362217B (es) 2019-01-09
BR112014015329A2 (pt) 2017-06-13
SG11201403075XA (en) 2014-07-30
HK1203365A1 (en) 2015-10-30
KR20140106720A (ko) 2014-09-03
KR20190110628A (ko) 2019-09-30
AU2021202042A1 (en) 2021-04-29
SG10201710667YA (en) 2018-02-27
ZA201804381B (en) 2022-12-21
IL233075A0 (en) 2014-07-31
SG10202012743WA (en) 2021-01-28
JP2015500886A (ja) 2015-01-08
EA034529B1 (ru) 2020-02-18
EA201491046A1 (ru) 2014-11-28
AU2019202602A1 (en) 2019-05-02
AU2017258916B2 (en) 2019-01-17
IN2014DN06117A (es) 2015-08-14
EP2793870A2 (en) 2014-10-29
KR20220047889A (ko) 2022-04-19
EA201992762A1 (ru) 2020-07-31
KR20210003313A (ko) 2021-01-11
IL285091A (en) 2021-08-31
WO2013096811A3 (en) 2014-07-24
KR102026321B1 (ko) 2019-09-27
BR112014015329A8 (pt) 2017-06-13
AU2017258916A1 (en) 2017-11-30
JP6255349B2 (ja) 2017-12-27
MX2014007350A (es) 2014-09-15

Similar Documents

Publication Publication Date Title
MX2023000320A (es) Metodos para modular los niveles de farmaco en plasma mediante el uso de eritrohidroxibupropion.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
MY163517A (en) Improved device and method for delivery of a medicament
PH12015500246A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
AU2011328009A8 (en) Compounds and methods for treating pain
MX340290B (es) Uso terapéutico de un agonista de receptor tipo toll y terapia de combinación.
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
MX365688B (es) Sistemas de administracion de farmaco y metodos para el tratamiento del cancer de vejiga que comprenden oxaliplatino.
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
MX2015012315A (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
WO2011100769A3 (en) Kinase modulators for the treatment of cancer
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX2021012154A (es) Dispositivos de administracion de farmacos por via transmucosal para uso en el alivio del dolor cronico.
CL2012000488A1 (es) Uso de carbon vegetal para tratar una sobredosis de etexilato de dabigatran.
EA201590760A1 (ru) Применение бремеланотида в терапии женской сексуальной дисфункции
UA86338U (ru) Способ лечения беременных с гестационным диабетом
AU2014900743A0 (en) A method to deliver pain relief with a reduced risk of overdose, using 1:1, 2:1, 3:1 and 4:1 mixtures of naloxone and fentanyl for nasal administration.
NZ724912A (en) Transmucosal drug delivery devices for use in chronic pain relief
UA67427U (ru) Способ лечения фиброзно-кавернозных форм органного туберкулеза